Combined genetic assessment of transforming growth factor-β signaling pathway variants may predict breast cancer risk

Virginia G. Kaklamani, Lisa Baddi, Junjian Liu, Diana Rosman, Sharbani Phukan, Ciarán Bradley, Chris Hegarty, Bree McDaniel, Alfred Rademaker, Carole Oddoux, Harry Ostrer, Loren S. Michel, Helen Huang, Yu Chen, Habibul Ahsan, Kenneth Offit, Boris Pasche

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

There is growing evidence that common variants of the transforming growth factor-β (TGF-β) signaling pathway may modify breast cancer risk. In vitro studies have shown that some variants increase TGF-β signaling, whereas others have an opposite effect. We tested the hypothesis that a combined genetic assessment of two well-characterized variants may predict breast cancer risk. Consecutive patients (n = 660) with breast cancer from the Memorial Sloan-Kettering Cancer Center (New York, NY) and healthy females (n = 880) from New York City were genotyped for the hypomorphic TGFBR1*6A allele and for the TGFB1 T29C variant that results in increased TGF-β circulating levels. Cases and controls were of similar ethnicity and geographic location. Thirty percent of cases were identified as high or low TGF-β signalers based on TGFB1 and TGFBR1 genotypes. There was a significantly higher proportion of high signalers (TGFBR1/TGFBR1 and TGFB1*CC) among controls (21.6%) than cases (15.7%; P = 0.003). The odds ratio [OR; 95% confidence interval (95% CI)] for individuals with the lowest expected TGF-β signaling level (TGFB1*TT or TGFB1*TC and TGFBR1*6A) was 1.69 (1.08-2.66) when compared with individuals with the highest expected TGF-signaling levels. Breast cancer risk incurred by low signalers was most pronounced among women after age 50 years (OR, 2.05; 95% CI, 1.01-4.16). TGFBR1*6A was associated with a significantly increased risk for breast cancer (OR, 1.46; 95% CI, 1.04-2.06), but the TGFB1*CC genotype was not associated with any appreciable risk (OR, 0.89; 95% CI, 0.63-1.21). TGFBR1*6A effect was most pronounced among women diagnosed after age 50 years (OR, 2.20; 95% CI, 1.25-3.87). This is the first study assessing the TGF-β signaling pathway through two common and functionally relevant TGFBR1 and TGFB1 variants. This approach may predict breast cancer risk in a large subset of the population.

Original languageEnglish (US)
Pages (from-to)3454-3461
Number of pages8
JournalCancer Research
Volume65
Issue number8
StatePublished - Apr 15 2005
Externally publishedYes

Fingerprint

Transforming Growth Factors
Breast Neoplasms
Confidence Intervals
Genotype
Geographic Locations
Alleles
Odds Ratio
Population
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kaklamani, V. G., Baddi, L., Liu, J., Rosman, D., Phukan, S., Bradley, C., ... Pasche, B. (2005). Combined genetic assessment of transforming growth factor-β signaling pathway variants may predict breast cancer risk. Cancer Research, 65(8), 3454-3461.

Combined genetic assessment of transforming growth factor-β signaling pathway variants may predict breast cancer risk. / Kaklamani, Virginia G.; Baddi, Lisa; Liu, Junjian; Rosman, Diana; Phukan, Sharbani; Bradley, Ciarán; Hegarty, Chris; McDaniel, Bree; Rademaker, Alfred; Oddoux, Carole; Ostrer, Harry; Michel, Loren S.; Huang, Helen; Chen, Yu; Ahsan, Habibul; Offit, Kenneth; Pasche, Boris.

In: Cancer Research, Vol. 65, No. 8, 15.04.2005, p. 3454-3461.

Research output: Contribution to journalArticle

Kaklamani, VG, Baddi, L, Liu, J, Rosman, D, Phukan, S, Bradley, C, Hegarty, C, McDaniel, B, Rademaker, A, Oddoux, C, Ostrer, H, Michel, LS, Huang, H, Chen, Y, Ahsan, H, Offit, K & Pasche, B 2005, 'Combined genetic assessment of transforming growth factor-β signaling pathway variants may predict breast cancer risk', Cancer Research, vol. 65, no. 8, pp. 3454-3461.
Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C et al. Combined genetic assessment of transforming growth factor-β signaling pathway variants may predict breast cancer risk. Cancer Research. 2005 Apr 15;65(8):3454-3461.
Kaklamani, Virginia G. ; Baddi, Lisa ; Liu, Junjian ; Rosman, Diana ; Phukan, Sharbani ; Bradley, Ciarán ; Hegarty, Chris ; McDaniel, Bree ; Rademaker, Alfred ; Oddoux, Carole ; Ostrer, Harry ; Michel, Loren S. ; Huang, Helen ; Chen, Yu ; Ahsan, Habibul ; Offit, Kenneth ; Pasche, Boris. / Combined genetic assessment of transforming growth factor-β signaling pathway variants may predict breast cancer risk. In: Cancer Research. 2005 ; Vol. 65, No. 8. pp. 3454-3461.
@article{c59193cca0bc4a9c9f913be1410e3d0c,
title = "Combined genetic assessment of transforming growth factor-β signaling pathway variants may predict breast cancer risk",
abstract = "There is growing evidence that common variants of the transforming growth factor-β (TGF-β) signaling pathway may modify breast cancer risk. In vitro studies have shown that some variants increase TGF-β signaling, whereas others have an opposite effect. We tested the hypothesis that a combined genetic assessment of two well-characterized variants may predict breast cancer risk. Consecutive patients (n = 660) with breast cancer from the Memorial Sloan-Kettering Cancer Center (New York, NY) and healthy females (n = 880) from New York City were genotyped for the hypomorphic TGFBR1*6A allele and for the TGFB1 T29C variant that results in increased TGF-β circulating levels. Cases and controls were of similar ethnicity and geographic location. Thirty percent of cases were identified as high or low TGF-β signalers based on TGFB1 and TGFBR1 genotypes. There was a significantly higher proportion of high signalers (TGFBR1/TGFBR1 and TGFB1*CC) among controls (21.6{\%}) than cases (15.7{\%}; P = 0.003). The odds ratio [OR; 95{\%} confidence interval (95{\%} CI)] for individuals with the lowest expected TGF-β signaling level (TGFB1*TT or TGFB1*TC and TGFBR1*6A) was 1.69 (1.08-2.66) when compared with individuals with the highest expected TGF-signaling levels. Breast cancer risk incurred by low signalers was most pronounced among women after age 50 years (OR, 2.05; 95{\%} CI, 1.01-4.16). TGFBR1*6A was associated with a significantly increased risk for breast cancer (OR, 1.46; 95{\%} CI, 1.04-2.06), but the TGFB1*CC genotype was not associated with any appreciable risk (OR, 0.89; 95{\%} CI, 0.63-1.21). TGFBR1*6A effect was most pronounced among women diagnosed after age 50 years (OR, 2.20; 95{\%} CI, 1.25-3.87). This is the first study assessing the TGF-β signaling pathway through two common and functionally relevant TGFBR1 and TGFB1 variants. This approach may predict breast cancer risk in a large subset of the population.",
author = "Kaklamani, {Virginia G.} and Lisa Baddi and Junjian Liu and Diana Rosman and Sharbani Phukan and Ciar{\'a}n Bradley and Chris Hegarty and Bree McDaniel and Alfred Rademaker and Carole Oddoux and Harry Ostrer and Michel, {Loren S.} and Helen Huang and Yu Chen and Habibul Ahsan and Kenneth Offit and Boris Pasche",
year = "2005",
month = "4",
day = "15",
language = "English (US)",
volume = "65",
pages = "3454--3461",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Combined genetic assessment of transforming growth factor-β signaling pathway variants may predict breast cancer risk

AU - Kaklamani, Virginia G.

AU - Baddi, Lisa

AU - Liu, Junjian

AU - Rosman, Diana

AU - Phukan, Sharbani

AU - Bradley, Ciarán

AU - Hegarty, Chris

AU - McDaniel, Bree

AU - Rademaker, Alfred

AU - Oddoux, Carole

AU - Ostrer, Harry

AU - Michel, Loren S.

AU - Huang, Helen

AU - Chen, Yu

AU - Ahsan, Habibul

AU - Offit, Kenneth

AU - Pasche, Boris

PY - 2005/4/15

Y1 - 2005/4/15

N2 - There is growing evidence that common variants of the transforming growth factor-β (TGF-β) signaling pathway may modify breast cancer risk. In vitro studies have shown that some variants increase TGF-β signaling, whereas others have an opposite effect. We tested the hypothesis that a combined genetic assessment of two well-characterized variants may predict breast cancer risk. Consecutive patients (n = 660) with breast cancer from the Memorial Sloan-Kettering Cancer Center (New York, NY) and healthy females (n = 880) from New York City were genotyped for the hypomorphic TGFBR1*6A allele and for the TGFB1 T29C variant that results in increased TGF-β circulating levels. Cases and controls were of similar ethnicity and geographic location. Thirty percent of cases were identified as high or low TGF-β signalers based on TGFB1 and TGFBR1 genotypes. There was a significantly higher proportion of high signalers (TGFBR1/TGFBR1 and TGFB1*CC) among controls (21.6%) than cases (15.7%; P = 0.003). The odds ratio [OR; 95% confidence interval (95% CI)] for individuals with the lowest expected TGF-β signaling level (TGFB1*TT or TGFB1*TC and TGFBR1*6A) was 1.69 (1.08-2.66) when compared with individuals with the highest expected TGF-signaling levels. Breast cancer risk incurred by low signalers was most pronounced among women after age 50 years (OR, 2.05; 95% CI, 1.01-4.16). TGFBR1*6A was associated with a significantly increased risk for breast cancer (OR, 1.46; 95% CI, 1.04-2.06), but the TGFB1*CC genotype was not associated with any appreciable risk (OR, 0.89; 95% CI, 0.63-1.21). TGFBR1*6A effect was most pronounced among women diagnosed after age 50 years (OR, 2.20; 95% CI, 1.25-3.87). This is the first study assessing the TGF-β signaling pathway through two common and functionally relevant TGFBR1 and TGFB1 variants. This approach may predict breast cancer risk in a large subset of the population.

AB - There is growing evidence that common variants of the transforming growth factor-β (TGF-β) signaling pathway may modify breast cancer risk. In vitro studies have shown that some variants increase TGF-β signaling, whereas others have an opposite effect. We tested the hypothesis that a combined genetic assessment of two well-characterized variants may predict breast cancer risk. Consecutive patients (n = 660) with breast cancer from the Memorial Sloan-Kettering Cancer Center (New York, NY) and healthy females (n = 880) from New York City were genotyped for the hypomorphic TGFBR1*6A allele and for the TGFB1 T29C variant that results in increased TGF-β circulating levels. Cases and controls were of similar ethnicity and geographic location. Thirty percent of cases were identified as high or low TGF-β signalers based on TGFB1 and TGFBR1 genotypes. There was a significantly higher proportion of high signalers (TGFBR1/TGFBR1 and TGFB1*CC) among controls (21.6%) than cases (15.7%; P = 0.003). The odds ratio [OR; 95% confidence interval (95% CI)] for individuals with the lowest expected TGF-β signaling level (TGFB1*TT or TGFB1*TC and TGFBR1*6A) was 1.69 (1.08-2.66) when compared with individuals with the highest expected TGF-signaling levels. Breast cancer risk incurred by low signalers was most pronounced among women after age 50 years (OR, 2.05; 95% CI, 1.01-4.16). TGFBR1*6A was associated with a significantly increased risk for breast cancer (OR, 1.46; 95% CI, 1.04-2.06), but the TGFB1*CC genotype was not associated with any appreciable risk (OR, 0.89; 95% CI, 0.63-1.21). TGFBR1*6A effect was most pronounced among women diagnosed after age 50 years (OR, 2.20; 95% CI, 1.25-3.87). This is the first study assessing the TGF-β signaling pathway through two common and functionally relevant TGFBR1 and TGFB1 variants. This approach may predict breast cancer risk in a large subset of the population.

UR - http://www.scopus.com/inward/record.url?scp=20244383746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244383746&partnerID=8YFLogxK

M3 - Article

C2 - 15833881

AN - SCOPUS:20244383746

VL - 65

SP - 3454

EP - 3461

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 8

ER -